For research use only. Not for therapeutic Use.
Imagabalin（Cat No.:I007274）is a selective modulator of the α2δ subunit of voltage-gated calcium channels, similar to gabapentin and pregabalin. It is being investigated for its potential in treating neurological conditions, including neuropathic pain, epilepsy, and anxiety disorders. By binding to the α2δ subunit, Imagabalin is thought to reduce the release of excitatory neurotransmitters, leading to a reduction in neuronal hyperexcitability. This mechanism may help alleviate pain and control seizures. While still under clinical investigation, Imagabalin shows promise as a treatment for conditions related to abnormal neuronal activity and excitability.
| Catalog Number | I007274 |
| CAS Number | 610300-07-7 |
| Synonyms | PD 0332334; PD0332334; PD-0332334; PD 332334; PD332334; PD-332334; PF-00195889; PF 00195889; PF00195889; PF-195889; PF 195889; PF195889; Imagabalin.;(3S,5R)-3-amino-5-methyloctanoic acid |
| Molecular Formula | C9H19NO2 |
| Purity | ≥95% |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4°C for short term , or -20°C for long term. |
| IUPAC Name | (3S,5R)-3-amino-5-methyloctanoic acid |
| InChI | InChI=1S/C9H19NO2/c1-3-4-7(2)5-8(10)6-9(11)12/h7-8H,3-6,10H2,1-2H3,(H,11,12)/t7-,8+/m1/s1 |
| InChIKey | JXEHXYFSIOYTAH-SFYZADRCSA-N |
| SMILES | CCC[C@@H](C)C[C@@H](CC(=O)O)N |
| Reference | 1:Protein Eng Des Sel. 2013 Jan;26(1):25-33. doi: 10.1093/protein/gzs065. Epub 2012 Sep 25. Redesigning and characterizing the substrate specificity and activity of Vibrio fluvialis aminotransferase for the synthesis of imagabalin.Midelfort KS,Kumar R,Han S,Karmilowicz MJ,McConnell K,Gehlhaar DK,Mistry A,Chang JS,Anderson M,Villalobos A,Minshull J,Govindarajan S,Wong JW, PMID: 23012440 DOI: 10.1093/protein/gzs065 </br><span>Abstract:</span> Several protein engineering approaches were combined to optimize the selectivity and activity of Vibrio fluvialis aminotransferase (Vfat) for the synthesis of (3S,5R)-ethyl 3-amino-5-methyloctanoate; a key intermediate in the synthesis of imagabalin, an advanced candidate for the treatment of generalized anxiety disorder. Starting from wild-type Vfat, which had extremely low activity catalyzing the desired reaction, we engineered an improved enzyme with a 60-fold increase in initial reaction velocity for transamination of (R)-ethyl 5-methyl 3-oxooctanoate to (3S,5R)-ethyl 3-amino-5-methyloctanoate. To achieve this, <450 variants were screened, which allowed accurate assessment of enzyme performance using a low-throughput ultra performance liquid chromatography assay. During the course of this work, crystal structures of Vfat wild type and an improved variant (Vfat variant r414) were solved and they are reported here for the first time. This work also provides insight into the critical residues for substrate specificity for the transamination of (R)-ethyl 5-methyl 3-oxooctanoate and structurally related β-ketoesters. |
